- Home
- OGEN vs RDHL Comparison
OGEN vs RDHL Comparison
Compare OGEN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- RDHL
- Stock Information
- Founded
- OGEN 1996
- RDHL 2009
- Country
- OGEN United States
- RDHL Israel
- Employees
- OGEN N/A
- RDHL N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- RDHL Health Care
- Exchange
- OGEN Nasdaq
- RDHL Nasdaq
- Market Cap
- OGEN 4.6M
- RDHL 3.8M
- IPO Year
- OGEN N/A
- RDHL N/A
- Fundamental
- Price
- OGEN $4.28
- RDHL $1.99
- Analyst Decision
- OGEN
- RDHL
- Analyst Count
- OGEN 0
- RDHL 0
- Target Price
- OGEN N/A
- RDHL N/A
- AVG Volume (30 Days)
- OGEN 599.0K
- RDHL 214.4K
- Earning Date
- OGEN 05-09-2025
- RDHL 04-10-2025
- Dividend Yield
- OGEN N/A
- RDHL N/A
- EPS Growth
- OGEN N/A
- RDHL N/A
- EPS
- OGEN N/A
- RDHL N/A
- Revenue
- OGEN N/A
- RDHL $8,042,999.00
- Revenue This Year
- OGEN N/A
- RDHL $381.91
- Revenue Next Year
- OGEN N/A
- RDHL N/A
- P/E Ratio
- OGEN N/A
- RDHL N/A
- Revenue Growth
- OGEN N/A
- RDHL 23.17
- 52 Week Low
- OGEN $3.12
- RDHL $1.71
- 52 Week High
- OGEN $75.60
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- OGEN 43.10
- RDHL 51.03
- Support Level
- OGEN $3.12
- RDHL $1.82
- Resistance Level
- OGEN $9.60
- RDHL $1.93
- Average True Range (ATR)
- OGEN 1.04
- RDHL 0.08
- MACD
- OGEN -0.12
- RDHL 0.04
- Stochastic Oscillator
- OGEN 17.90
- RDHL 100.00
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.